Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.1% – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price traded up 8.1% during mid-day trading on Thursday . The company traded as high as $7.40 and last traded at $7.31. 6,584,147 shares traded hands during mid-day trading, a decline of 5% from the average session volume of 6,933,797 shares. The stock had previously closed at $6.76.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals has an average rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Trading Up 4.1 %

The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of -4.60 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average is $6.82 and its 200 day moving average is $7.09.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s revenue for the quarter was up 147.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.43) earnings per share. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. The trade was a 0.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total value of $76,351.49. Following the completion of the transaction, the director now owns 7,089,007 shares of the company’s stock, valued at $47,283,676.69. The trade was a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 70,341 shares of company stock valued at $488,290 in the last quarter. 15.75% of the stock is currently owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC raised its holdings in shares of Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after purchasing an additional 4,626,268 shares during the period. State Street Corp increased its position in Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. FMR LLC raised its stake in Recursion Pharmaceuticals by 2.1% in the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock valued at $55,116,000 after buying an additional 170,810 shares during the period. Geode Capital Management LLC lifted its position in shares of Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after buying an additional 656,003 shares during the last quarter. Finally, Lingotto Investment Management LLP boosted its stake in shares of Recursion Pharmaceuticals by 69.0% during the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock worth $27,563,000 after acquiring an additional 1,500,000 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.